A multimarker study of degenerative aortic valve disease: Stenoinsufficiency shows more indices of bad prognosis

Cardiology (Switzerland)

Volumn 124, Issue 2, 2013, Pages 126-137

  Vianello, Annamaria ^a   Perlini, Stefano ^b   Cappelli, Stefania ^c   Palladini, Giuseppina ^b   Epistolato, Maria Carmela ^c   Della Latta, Daniele ^d   Cerillo, Alfredo ^d   Berti, Sergio ^d   Chiappino, Dante ^d   Tanganelli, Piero ^c   Glauber, Mattia ^d   Mazzone, Annamaria ^d  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

Author keywords

Atherosclerosis; Clinical outcome; Degenerative aortic valve disease; Stenoinsufficiency

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GELATINASE A; GELATINASE B; OSTEOPONTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; BIOLOGICAL MARKER; METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; AGED; AORTA VALVE DISEASE; AORTA VALVE REGURGITATION; AORTIC VALVE STENOINSUFFICIENCY; ARTICLE; CALCIFICATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; DEGENERATIVE AORTIC VALVE DISEASE; DISEASE MARKER; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VALVE BIOPROSTHESIS; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PURE VALVE STENOSIS; SURGICAL PATIENT; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE; CAROTID ATHEROSCLEROSIS; HEART DISEASE; HEART VALVE STENOSIS; HEART VENTRICLE REMODELING; HUMAN TISSUE; MEDICAL DECISION MAKING; MORTALITY; PATHOPHYSIOLOGY; SCORING SYSTEM; ULTRASOUND; VALVULAR HEART DISEASE;

AGED; AORTIC VALVE INSUFFICIENCY; AORTIC VALVE STENOSIS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BIOPROSTHESIS; CAROTID STENOSIS; CASE-CONTROL STUDIES; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; METALLOPROTEASES; NATRIURETIC PEPTIDE, BRAIN; OSTEOPONTIN; PROGNOSIS; PROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASES; VASCULAR CALCIFICATION;

EID: 84874009183     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000346396     Document Type: Article

References (34)

1. Goldbarg SH, Elmarich S, Miller MA, Fuster V: Insights into degenerative aortic valve disease. J Am Coll Cardiol 2007; 50: 1205-1213.
2. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS: Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999; 34: 142-147.
3. Otto CM: Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol 2006; 47: 2141-2151.
4. Mazzone A, Epistolato MC, De Caterina R, Storti S, Vittorini S, Sbrana S, Gianetti J, Bevilacqua S, Glauber M, Biagini A, Tanganelli P: Neoangiogenesis, T-lymphocyte infiltration, and shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol 2004; 43: 1670-1676.
5. Mazzone A, Epistolato MC, Gianetti J, Castagnini M, Sassi C, Ceravolo R, Bevilacqua S, Glauber M, Biagini A, Tanganelli P: Biological features (inflammation and neoangiogenesis) and atherosclerosis risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease? Am J Clin Pathol 2006; 126: 494-502.
6. Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Despres JP, Arsenault M, Couet J, Pibarot P: Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006; 47: 2229-2236.
7. Rajamannan NM: Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 2009; 29: 162-168.
8. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM: Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptormediated bone formation. J Am Coll Cardiol 2006; 47: 1707-1712.
9. Scatena M, Liaw L, Giachelli GM: Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Atherioscler Thromb Vasc Biol 2007; 27: 2302-2309.
10. Fondard O, Detaint D, Iung B, Choqueux C, Adle-Biassette H, Jarraya M, Hvass U, Couetil JP, Henin D, Michel JB, Vahanian A, Jacob MP: Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 2005; 26: 1333-1341.
11. Balachandran K, Sucosky P, Jo H, Yoganathan AP: Elevated cyclic stretch alters matrix remodeling in aortic valve cups. Implications for degenerative aortic valve disease? Am J Physiol Heart Circ Physiol 2009; 296:H756-H764.
12. Pedrazzini GB, Masson S, Latini R, Klersy C, Rossi MG, Pasotti E, Faletra FF, Siclari F, Minervini F, Moccetti T, Auricchio A: Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting inhospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis. Am J Cardiol 2008; 102: 749-754.
13. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA: Controversies in ventricular remodelling. Lancet 2006; 367: 356-367.
14. Laissy JP, Messika-Zeitoun D, Serfaty JM, Sebban V, Schouman-Claeys E, Iung B, Vahanian A: Comprehensive evaluation of preoperative patients with aortic valve stenosis: usefulness of cardiac multidetector computed tomography. Heart 2007; 93: 1121-1125.
15. Miller JD, Weiss RM, Serrano KM, Brooks RM 2nd, Berry CJ, Zimmerman K, Young SG, Heistad DD: Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 2009; 119: 2693-2701.
16. Rajamannan NM, Subramaniam M, Caira FC, Stock SR, Spelsberg TC: Atorvastatin inhibits hypercholesterolemia induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005; 112(suppl 9):1229-1234.
17. Monzack EL, Gu X, Masters KS: Efficacy of simvastatin treatment of valvular interstitial cells varies with the extracellular environment. Arterioscler Thromb Vasc Biol 2009; 29: 246-253.
18. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD: Low-gradient aortic valve stenosis: myocardial fibrosis and its influence on function and outcome. Lancet 2002; 359: 1125-1126.
19. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H: Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004; 110: 1291-1295.
20. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Goncalves F, Rajamannan NM: Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007; 49: 554-561.
21. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA, Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352: 2389-2397.
22. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-1356.
23. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, ASTRONOMER Investigators: Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010; 121: 306-314.
24. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, Iung B, Otto CM, Pellikka PA, Quinones M, American Society of Echocardiography, European Association of Echocardiography: Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009; 22: 1-23.
25. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832.
26. Tozzi R, Palladini G, Fallarini S, Nano R, Gatti C, Presotto C, Schiavone A, Micheletti R, Ferrari P, Fogari R, Perlini S: Matrix metalloproteinase activity is enhanced in the compensated but not in the decompensated phase of pressure overload hypertrophy. Am J Hypertens 2007; 20: 663-669.
27. Truter SL, Catanzaro DF, Supino PG, Gupta A, Carter J, Herrold EM, Dumlao TF, Borer JS: Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts. Cardiology 2009; 113: 161-168.
28. Yan AT, Yan RT, Spinale FG, Afzal R, Gunasinghe HR, Stroud RE, McKelvie RS, Liu PP: Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail 2008; 10: 125-128.
29. Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, Schulz-Menger J: Noninvasive detection of fibrosis applying contrastenhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy. Relation to remodeling. J Am Coll Cardiol 2009; 53: 284-291.
30. Catovic S, Popovic ZB, Tasic N, Nezic D, Milojevic P, Djukanovic B, Gradinac S, Angelkov L, Otasevic P: Impact of concomitant aortic regurgitation on long-term outcome after surgical aortic valve replacement in patients with severe aortic stenosis. J Cardiothorac Surg 2011; 6: 51.
31. Nadir MA, Wei L, Elder DH, Libianto R, Lim TK, Pauriah M, Pringle SD, Doney AD, Choy AM, Struthers AD, Lang CC: Impact of reninangiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol 2011; 58: 570-576.
32. Freeman RV, Otto CM: Spectrum of calcific aortic valve disease. Pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111: 3316-3326.
33. Herrmann S, Stork S, Niemann M, Lange V, Strotmann JM, Frantz S, Beer M, Gattenlohner S, Voelker W, Ertl G, Weidemann F: Lowgradient aortic valve stenosis: myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol 2011; 58: 402-412.
34. Pibarot P, Dumesnil LG: Paradoxical lowflow, low-gradient aortic stenosis. J Am Coll Cardiol 2011; 58: 413-415.